Sonnet BioTherapeutics Holdings (SONN) said Monday its phase 1 trial of SON-1010 demonstrated a partial response and disease stabilization in adult patients with advanced solid tumors.
One patient in the highest-dose cohort experienced a 45% tumor reduction per RECIST criteria, while 48% of evaluable patients maintained stability at four months, the company said.
No dose-limiting toxicities or related serious adverse events have been reported, with most adverse events being mild and transient, Sonnet said.
Shares of the company surged nearly 116% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。